FDA OKs Generic Antidepressant

Thursday, 12 Dec 2013 12:52 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

The first generic versions of the antidepressant drug Cymbalta (duloxetine delayed-release capsules) have been approved by the U.S. Food and Drug Administration.

License to produce generic Cymbalta was granted to Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharma Global FZE, Teva Pharmaceuticals USA, and Torrent Pharmaceuticals Ltd., the agency said Wednesday in a news release.

Duloxetine is prescribed to treat symptoms of depression, which may include: depressed mood, loss of interest in usual activities, changes in weight or appetite, sleep problems, feelings of guilt or worthlessness, inability to concentrate or suicidal thoughts, the FDA said.

Labeling on duloxetine and other antidepressants says these drugs could increase users' risks of suicidal thinking and behavior, particularly among children, teens and young adults. Users should be monitored closely for these warning signs, the agency advised.

Common side effects of duloxetine include nausea, dry mouth, drowsiness, loss of appetite, increased sweating and dizziness.

Generic drugs are equivalent in effect and strength to their brand-name counterparts, the FDA said.

© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved